论文部分内容阅读
目的:观察奥沙利铂(OXA)联合氟尿嘧啶(5-Fu)、亚叶酸钙(CF)组成的FOLFOX7方案治疗晚期胃癌的疗效和不良反应。方法:43例晚期胃癌患者接受奥沙利铂130mg/m2,第1天静脉滴注3h;亚叶酸钙400mg/m2,第1天静脉滴注2h;氟尿嘧啶2400mg/m2,静脉持续滴注46h,14天为1周期,应用2个周期后评价疗效。结果:43例共完成178个周期化疗,中位数4个周期(1～6个周期)。41例可评价疗效,总有效率(ORR)48.7%(20/41),完全缓解(CR)4.8%(2/41),部分缓解(PR)43.9%(18/41),稳定(SD)41.4%(17/41),进展(PD)9.7%(4/41)。1年生存率为43.9%(18/41)。43例可评价毒性,主要的不良反应为胃肠道反应,发生率88.3%(38/41),白细胞减少39.6%(17/43),神经毒性11.6%(5/43)。结论:FOLFOX7方案治疗晚期胃癌不良反应可耐受。
Objective: To observe the efficacy and side effects of oxaliplatin (OXA) combined with 5-fluorouracil (5-Fu) and leucovorin (CF) in the treatment of advanced gastric cancer. Methods: Forty-three patients with advanced gastric cancer received oxaliplatin 130 mg / m 2 intravenously for 3 hours on day 1; leucovorin 400 mg / m 2 for intravenous drip on day 1; fluorouracil 2400 mg / 14 days for a cycle, evaluation of 2 cycles after the application of efficacy. RESULTS: A total of 43 cycles completed 178 cycles of chemotherapy with a median of 4 cycles (1 to 6 cycles). Forty-one patients were evaluated for efficacy, with an overall response rate of 48.7% (20/41), complete remission (CR) 4.8% (2/41), partial response (43.9% 41.4% (17/41), progress (PD) 9.7% (4/41). The 1-year survival rate was 43.9% (18/41). Forty-three patients were evaluated for toxicity. The major adverse reactions were gastrointestinal reactions, with a rate of 88.3% (38/41), leukopenia 39.6% (17/43) and neurotoxicity 11.6% (5/43). Conclusion: FOLFOX7 regimen can tolerate the adverse reactions of advanced gastric cancer.